Yorkshire Cancer Research’s response to the UK National Screening Committee’s Population Screening for Bladder Cancer 2025 Evidence Map

The UK National Screening Committee recently published an evidence map regarding screening for bladder cancer. This concluded that there was not enough evidence to support a more comprehensive review of the evidence and that the Committee will reconsider the evidence in three years’ time. The evidence map cites the YORKSURe trial as a key example of research which will increase the existing evidence base on bladder cancer screening.  

In this response, Yorkshire Cancer Research explains how the YORKSURe trial will increase the evidence on the feasibility of bladder cancer screening. This trial will assess and compare the use of urine self-testing kits and community early-detection clinics in diagnosing people at high risk of developing bladder cancer.

The response also recommends that future screening studies are focussed on high risk populations, including men who currently or formerly smoke and people working in high risk occupations such as factory work.